2018
DOI: 10.3791/58219-v
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Currently, manipulating placental gene expression in vivo requires transgenic animal technology, which is labor-intensive and time-consuming ( 58 ). Thus, we optimized a nanoparticle-based system for manipulating gene expression, specifically in the placenta in vivo ( 33 ). Nanoparticle-mediated trophoblastic ADM knockdown resulted in premature lethality of embryo at E15.5 and reduced fetal blood vessel branching in the labyrinth, recapitulating phenotypes observed in the ovary transplantation model, which showed that the loss of fetal ADM contributes to premature death of embryos and dysregulated fetal blood morphology ( 21 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, manipulating placental gene expression in vivo requires transgenic animal technology, which is labor-intensive and time-consuming ( 58 ). Thus, we optimized a nanoparticle-based system for manipulating gene expression, specifically in the placenta in vivo ( 33 ). Nanoparticle-mediated trophoblastic ADM knockdown resulted in premature lethality of embryo at E15.5 and reduced fetal blood vessel branching in the labyrinth, recapitulating phenotypes observed in the ovary transplantation model, which showed that the loss of fetal ADM contributes to premature death of embryos and dysregulated fetal blood morphology ( 21 ).…”
Section: Discussionmentioning
confidence: 99%
“…The specific targeting placenta of LNP in vivo was studied using placental chondroitin sulfate A–binding peptide (plCSA-BP)–coated LNP by an established mouse model ( 33 ). Placental CSA-binding peptide was purchased from China Peptides Co. Ltd. (Shanghai, China).…”
Section: Methodsmentioning
confidence: 99%